<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563184</url>
  </required_header>
  <id_info>
    <org_study_id>Flu Vaccine Quad vs Tri</org_study_id>
    <nct_id>NCT02563184</nct_id>
  </id_info>
  <brief_title>Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Banner Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the magnitude of the humoral immune responses to quadrivalent vs trivalent&#xD;
      influenza vaccines in adults between the age of 50 and 64 years with a prior diagnosis of&#xD;
      GOLD Stage C and D COPD vs. those patients without COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To evaluate the magnitude of the humoral immune responses to quadrivalent vs trivalent&#xD;
      influenza vaccines in adults between the age of 50 and 64 years with a prior diagnosis of&#xD;
      GOLD Stage C and D COPD (vs. those patients without COPD).&#xD;
&#xD;
      To demonstrate immunogenicity by measuring hemagglutination inhibiting antibodies (HI)&#xD;
      against the components of viral antigens using seroconversion (≥4 fold increase over baseline&#xD;
      titers) and sero-protection (HI titer of ≥40 against the vaccine components).&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the degree of antibody response of COPD patients based on severity of disease as&#xD;
      measured by FEV1.&#xD;
&#xD;
      To assess the impact of inhaled corticosteroids on the adaptive immune response after&#xD;
      vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination inhibiting antibodies (HI) against the components of viral antigens</measure>
    <time_frame>3 months</time_frame>
    <description>The investigators will be measuring hemagglutination inhibiting antibodies (HI) against the components of viral antigens using seroconversion (≥4 fold increase over baseline titers) and sero-protection (HI titer of ≥40 against the vaccine components)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for patients with COPD will be:&#xD;
&#xD;
          1. Signed informed consent prior to initiation of study-mandated vaccination.&#xD;
&#xD;
          2. Patients with spirometric data in the preceding 18 months confirming the diagnosis of&#xD;
             COPD.&#xD;
&#xD;
          3. Patients meeting GOLD Classification of Stage C or Stage D COPD.&#xD;
&#xD;
          4. Patients 50 years old - 64 years old.&#xD;
&#xD;
        Inclusion criteria for Healthy participants will be:&#xD;
&#xD;
          1. Signed informed consent prior to initiation of study-mandated vaccination.&#xD;
&#xD;
          2. No active symptoms of lung disease.&#xD;
&#xD;
          3. FEV1/FVC in the normal range &gt; 70% age predicted value.&#xD;
&#xD;
          4. No history of tobacco use/abuse.&#xD;
&#xD;
          5. No prior history of alpha-1 antitrypsin deficiency.&#xD;
&#xD;
          6. Patients 50 years old - 64 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe allergy to eggs.&#xD;
&#xD;
          2. Severe reaction to past doses of influenza vaccine.&#xD;
&#xD;
          3. Guillian-Barre syndrome.&#xD;
&#xD;
          4. Currently recieving dialysis.&#xD;
&#xD;
          5. Current, active, treatment for cancer.&#xD;
&#xD;
          6. History of transplant (allograft).&#xD;
&#xD;
          7. Dementia or Alzheimer's disease diagnosis.&#xD;
&#xD;
          8. Prior diagnosis of HIV or AIDS.&#xD;
&#xD;
          9. Moderate to severe pulmonary hypertension.&#xD;
&#xD;
         10. Serum AST/ALT &gt; 3x the upper limit of normal.&#xD;
&#xD;
         11. Patients with exacerbations or respiratory infection during the 4 weeks preceding the&#xD;
             onset of the study.&#xD;
&#xD;
         12. Active pregnancy.&#xD;
&#xD;
         13. Systemic immunomodulating medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunny Sambhara, MD</last_name>
      <phone>602-258-4951</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Banner Health</investigator_affiliation>
    <investigator_full_name>David Baratz, M.D.</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

